BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27858708)

  • 1. Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.
    Paraskevas GP; Kasselimis D; Kourtidou E; Constantinides V; Bougea A; Potagas C; Evdokimidis I; Kapaki E
    J Alzheimers Dis; 2017; 55(4):1453-1461. PubMed ID: 27858708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia.
    Santangelo R; Coppi E; Ferrari L; Bernasconi MP; Pinto P; Passerini G; Comi G; Magnani G
    J Alzheimers Dis; 2015; 43(4):1429-40. PubMed ID: 25201781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
    Lleó A; Irwin DJ; Illán-Gala I; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    JAMA Neurol; 2018 Jun; 75(6):738-745. PubMed ID: 29554190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer's Disease and Frontotemporal Dementias.
    Constantinides VC; Paraskevas GP; Boufidou F; Bourbouli M; Pyrgelis ES; Stefanis L; Kapaki E
    Diagnostics (Basel); 2023 Feb; 13(4):. PubMed ID: 36832271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
    de Souza LC; Lamari F; Belliard S; Jardel C; Houillier C; De Paz R; Dubois B; Sarazin M
    J Neurol Neurosurg Psychiatry; 2011 Mar; 82(3):240-6. PubMed ID: 20802215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Otto M; Kornhuber J; Rüther E; Wiltfang J
    Dement Geriatr Cogn Disord; 2011; 31(1):37-44. PubMed ID: 21135556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No added diagnostic value of non-phosphorylated tau fraction (p-tau
    Goossens J; Bjerke M; Struyfs H; Niemantsverdriet E; Somers C; Van den Bossche T; Van Mossevelde S; De Vil B; Sieben A; Martin JJ; Cras P; Goeman J; De Deyn PP; Van Broeckhoven C; van der Zee J; Engelborghs S
    Alzheimers Res Ther; 2017 Jul; 9(1):49. PubMed ID: 28709448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration.
    Ortner M; Goldhardt O; Diehl-Schmid J; Yakushev I; Lanz K; Hedderich DM; Manuilova E; Simon M; Weinberger JP; Grimmer T
    J Prev Alzheimers Dis; 2022; 9(3):491-498. PubMed ID: 35841250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia.
    Borroni B; Benussi A; Archetti S; Galimberti D; Parnetti L; Nacmias B; Sorbi S; Scarpini E; Padovani A
    Amyotroph Lateral Scler Frontotemporal Degener; 2015 Mar; 16(1-2):86-91. PubMed ID: 25352065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
    Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
    J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.
    Baldeiras I; Santana I; Leitão MJ; Ribeiro MH; Pascoal R; Duro D; Lemos R; Santiago B; Almeida MR; Oliveira CR
    J Neurol Sci; 2015 Nov; 358(1-2):308-16. PubMed ID: 26388316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration.
    Kapaki E; Paraskevas GP; Papageorgiou SG; Bonakis A; Kalfakis N; Zalonis I; Vassilopoulos D
    Alzheimer Dis Assoc Disord; 2008; 22(1):47-53. PubMed ID: 18317246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
    Alcolea D; Vilaplana E; Suárez-Calvet M; Illán-Gala I; Blesa R; Clarimón J; Lladó A; Sánchez-Valle R; Molinuevo JL; García-Ribas G; Compta Y; Martí MJ; Piñol-Ripoll G; Amer-Ferrer G; Noguera A; García-Martín A; Fortea J; Lleó A
    Neurology; 2017 Jul; 89(2):178-188. PubMed ID: 28592456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasias.
    Mendes A; Bertrand A; Lamari F; Colliot O; Routier A; Godefroy O; Etcharry-Bouyx F; Moreaud O; Pasquier F; Couratier P; Bennys K; Vercelletto M; Martinaud O; Laurent B; Pariente J; Puel M; Epelbaum S; Belliard S; Kaaouana T; Fillon L; Chupin M; Dubois B; Teichmann M;
    Neurology; 2018 Mar; 90(12):e1057-e1065. PubMed ID: 29444966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
    Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abeta peptide 1-42, Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia.
    Maeck L; Meller J; Otto M; Stiens G; Wiltfang J; Stoppe G
    Neurosci Lett; 2002 Nov; 333(1):33-6. PubMed ID: 12401554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum.
    Meeter LHH; Vijverberg EG; Del Campo M; Rozemuller AJM; Donker Kaat L; de Jong FJ; van der Flier WM; Teunissen CE; van Swieten JC; Pijnenburg YAL
    Neurology; 2018 Apr; 90(14):e1231-e1239. PubMed ID: 29514947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.